相关实验视频
Updated: Jan 6, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
在没有认知障碍的老年人中,化的Tau 217和粉样蛋白负担:元分析
Michael Malek-Ahmadi1,2, Savar Sharma3, Fawaz Stipho4
1Banner Alzheimer's Institute, Phoenix, Arizona.
JAMA neurology
|December 1, 2025
概括
化217 (p-tau217) 可靠地检测老年人的临床前阿尔茨海默病 (AD) 病理. 这种血液生物标志物具有很高的准确性,支持其用于早期AD识别和干预.
科学领域:
- 神经学和神经科学 神经学和神经科学
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 基于血液的生物标志物 (BBM) 显示出阿尔茨海默病 (AD) 检测的希望.
- 化217 (p-tau217) 是阿尔茨海默氏症病理学的一个强有力的候选生物标志物.
- 它在没有认知障碍的粉样蛋白阳性个体中的实用性需要进一步验证.
研究的目的:
- 评估血p-tau217的诊断准确性,以识别没有认知障碍的粉样蛋白阳性个体.
- 为了确定粉素阳性和粉素阴性老年人之间的p-tau217差异的标准化效应大小.
主要方法:
- 发表的研究的系统审查和元分析 (PubMed,Embase,EBSCOhost).
- 包括观察性研究和带有基线数据的RCT在认知上未受损的粉样蛋白阳性/阴性个体.
- 分析了来自18个出版物的数据,涉及7834名参与者.
主要成果:
- 对p-tau217观察到一个很大的效果大小 (Hedges g = 1.50).
- 血p-tau217在识别粉样蛋白阳性 (AUC = 0.87) 中表现出高准确度.
- 结果在各个子组和敏感性分析中一致,出版偏差最小.
结论:
- 血p-tau217可靠地检测到临床前阿尔茨海默病的病理.
- 这种生物标志物支持临床实用性,作为早期AD识别的可扩展,最少侵入性的工具.
- 早期识别有助于及时干预疾病修饰疗法.
相关概念视频
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
01:30Dementia
480
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
480